View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this "Ask Me Anything" (AMA) episode, Peter explores the evidence behind environmental pollution and its impact on long-term health, separating well-supported risks from less substantiated claims while providing a practical framework for deciding which exposures deserve attention. He explains what environmental pollution encompasses, where it fits within the broader hierarchy of longevity interventions, and why studying its health effects is uniquely challenging. Peter examines the evidence linking air pollution to disease and shares actionable strategies for improving indoor and outdoor air quality. He also discusses how noise and light pollution can influence sleep, cardiovascular health, and overall well-being, offering practical ways to reduce their effects in daily life. Finally, Peter takes an evidence-based look at electromagnetic fields (EMFs) and 5G technology, evaluating the current science and whether concerns about these exposures are supported by the available data. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #87 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Gayatri Devi is a nationally recognized neurologist specializing in memory disorders, including Alzheimer's disease and related dementias. In this episode, Gayatri explains how to think about dementia as a spectrum—including Alzheimer's disease, vascular dementia, Lewy body dementia, and mixed presentations—while exploring the evolving biology of amyloid, tau, and neuroinflammation and why brain pathology does not always correlate with symptoms. She discusses her approach to detecting subtle cognitive decline in high-functioning individuals, the role of biomarkers and APOE4 testing in asymptomatic patients, the benefits and risks of anti-amyloid therapies such as lecanemab and donanemab, and strategies for minimizing treatment-related complications. Gayatri also examines why some patients may stabilize or even improve with individualized care, the overlap among different dementia syndromes, and the relationship between menopause, estrogen, and cognition—including her concept of menopause-related cognitive impairment. Finally, she discusses how advances in early detection, AI-assisted monitoring, targeted therapies, and precision medicine are reshaping the future of dementia care. We discuss: Gayatri's training and clinical focus, why dementia is a spectrum disease, and how personalized treatment is changing Alzheimer's care [3:45]; How Alzheimer's disease fits within the broader spectrum of dementia: diagnosis, biomarkers, and early pathophysiology [7:15]; The emerging role of neuroinflammation and viral infections in Alzheimer's disease [13:30]; Gayatri's comprehensive approach to evaluating cognitive decline in high-functioning patients [17:45]; Why forgetting names is usually normal and when wor

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this "Ask Me Anything" (AMA) episode, Peter dives deep into the topic of muscle mass and strength, examining their essential roles in both lifespan and healthspan. Drawing from over 30 hours of prior discussions with experts including Layne Norton, Andy Galpin, and Mike Israetel, this episode distills the most important insights into one comprehensive and up-to-date conversation. Peter explores why muscle matters for longevity, metabolic health, and injury prevention, and clarifies the differences between muscle mass and strength, including which is more vital for aging well. He breaks down practical strategies for building muscle safely and effectively, including progressive overload, training intensity, rep ranges, and the importance of explosive power. Peter also covers key nutrition strategies—like protein intake, timing, and creatine supplementation—and offers practical advice for everyone from beginners to seasoned lifters on building and maintaining muscle safely and sustainably. We discuss: Peter's humorous experience talking nutrition with a second grader [3:00]; Overview of topics, episode structure, and reasoning for focus on muscle mass and strength [6:30]; Defining key terms: muscle mass, strength, hypertrophy, power, and more [8:45]; The importance of muscular strength, muscle mass, and cardiorespiratory fitness for longevity [11:00]; Grip strength as a simple yet powerful predictor of all-cause mortality [17:15]; Is muscle strength causal or just a marker of health? [20:30]; Why VO2 max, strength, and muscle mass are powerful health markers: a reflection of long-term consistent effort [23:00]; How muscle ma

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this "Ask Me Anything" (AMA) episode, Peter explores the effects of GLP-1 receptor agonists—including drugs such as Ozempic, Wegovy, and Zepbound—with a particular focus on their impact on muscle. He examines how much lean mass people actually lose during treatment and how those changes compare to weight loss achieved through other methods, while explaining why measurements of lean mass on DEXA scans can sometimes be misleading. Peter discusses the effects of these medications on bone mass, fracture risk, strength, and physical function, highlighting why functional outcomes may be more important than body composition metrics alone. He also explores how GLP-1–based therapies affect different fat depots throughout the body, identifies who may be most vulnerable to muscle loss, and outlines practical strategies for preserving muscle and bone health while using these medications. Finally, Peter reviews early insights into retatrutide, a next-generation weight-loss therapy, including what current evidence suggests about its effects on weight loss and muscle mass. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #86 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits 

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter View our full terms of use Renato Tomioka is a leading expert in reproductive medicine and gynecologic surgery whose unique skills allow him to diagnose and treat some of the most impactful yet frequently overlooked conditions affecting women's health. In this episode, Renato explores endometriosis and adenomyosis, explaining what these conditions are, why they often go undiagnosed for years despite affecting millions of women worldwide, and how advances in MRI and specialized ultrasound are transforming diagnosis beyond traditional surgical laparoscopy. He discusses the decision-making process behind hormonal therapy versus surgery, how treatment strategies change when fertility preservation is a priority, and where IVF fits into the care pathway for women with endometriosis, adenomyosis, or age-related fertility decline. Renato also examines the profound effects of female age on egg quality and quantity, including the accelerating rise in chromosomal abnormalities after age 35, highlights common mistakes in both surgical and fertility management, and shares promising developments on the horizon for treating these conditions and preserving fertility. Follow Dr. Tomioka's work: Instagram: @dr.renatotomioka; Website: Renato Tomioka, M.D., Ph.D. We discuss: 0:00:00 - Intro 0:00:11 - Endometriosis: definition, prevalence, infer

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this episode, Peter explores the critical topic of breast cancer screening, examining why thousands of women continue to die from breast cancer each year despite the availability of effective screening tools. He explains the strengths and limitations of current screening strategies, reviews the recommendations from major medical organizations, and discusses why screening guidance can often seem confusing or contradictory. Peter outlines a practical framework for understanding breast cancer risk and personalizing screening decisions, including when to begin screening, how frequently to screen, and which imaging modalities may be most appropriate based on an individual's risk profile. Throughout the episode, he emphasizes that while population-based guidelines provide an important foundation, optimizing outcomes requires a more personalized approach aimed at helping women make informed screening decisions that can improve the chances of early detection and successful treatment. We discuss: Why women still die from breast cancer: the benefits of screening, the problem of under-screening, and the need for risk-based screening strategies [1:45]; Current screening recommendations, why they differ between organizations, and the importance of personalized screening decisions [6:30]; A framework for personalizing screening [8:45]; Assessing baseline breast cancer risk: genetics, family history, breast density, lifestyle factors, and the role of risk calculators in personalized screening [9:30]; Balancing cancer detection and false positives: how breast cancer risk influences screening intensity and imaging choices [17:45];

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Tom Dayspring is a world-renowned lipidologist and one of the most thoughtful teachers in the field of lipid metabolism. In this episode, Tom returns to The Drive for a deep dive into the relationship between lipids and brain health, beginning with the fundamentals of cholesterol transport before exploring why the brain's cholesterol system operates almost entirely independently from the rest of the body. Tom examines the roles of apoB, apoA-I, and especially apoE in cholesterol homeostasis, discusses how APOE genotype influences Alzheimer's disease risk, and unpacks the complex links between cholesterol metabolism, amyloid, and tau pathology. He also reviews what is currently known—and still uncertain—about the effects of statins, ezetimibe, omega-3 fatty acids, and emerging CETP inhibitors on brain health and neurodegenerative disease risk. Although highly technical, this conversation provides an essential framework for understanding the nuanced relationship between lipid-lowering therapies, cardiovascular disease prevention, and neurodegenerative diseases in an area often clouded by misinformation. We discuss: The fundamentals of cholesterol transport in the body, and how peripheral cholesterol metabolism differs from cholesterol handling in the brain [2:45]; How cholesterol is transported through plasma and stored within cells, and why lowering LDL cholesterol does not deplete the body or brain of cholesterol [11:45]; How apoB particles drive atherosclerosis, why lowering lipids matters, and the factors that influence individual cardiovascular risk [20:00]; How the brain produces and transports its own cholesterol using apoE lipoproteins independently of circulating cholesterol and apoB-co

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this episode, Peter dives into the pharmacology of sleep, exploring where sleep medications fit within the broader framework of achieving healthy, restorative sleep. He explains why sleep is a biological imperative, why behavioral and environmental interventions must remain the foundation of good sleep, and how medications can serve as useful tools when carefully matched to a person's specific sleep problem. Peter examines the major classes of prescription sleep medications, including how they work, their effects on sleep architecture, their duration of action, side effects, and risks of tolerance and dependence. He also discusses the dangers of using sleep drugs without a clear understanding of the underlying problem being treated, the role of medications as short-term bridges during periods of acute stress, pain, or anxiety, and the promise that newer drugs like DORAs may hold for Alzheimer's prevention in high-risk individuals. Finally, Peter reviews the evidence for select off-label medications and supplements commonly used for sleep. We discuss: The biological foundations of sleep, the major drivers of sleep dysfunction, and the role sleep medications can play when appropriately matched to specific sleep problems [1:00]; Sleep hygiene, circadian alignment, and the medical causes of insomnia: building the foundation for effective sleep treatment [7:15]; Understanding insomnia: hyperarousal, CBT-I, paradoxical insomnia, and why different sleep problems require different treatments [12:45]; The difference between sedation and physiologic sleep: sleep architecture, restorative sleep stages, and matching medications to specific sleep problems [17:00]; Be

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this "Ask Me Anything" (AMA) episode, Peter explores how to think critically about medications and supplements by focusing not on whether an intervention is inherently "good" or "bad," but on whether it makes sense for a specific person with a specific problem. He explains why clearly defining the problem matters more than choosing the intervention itself, how the intended purpose of a medication or supplement should influence the standard of evidence required, and why mechanistic reasoning alone is rarely enough to justify taking something. Peter also examines how baseline risk shapes the true benefit of an intervention, why relative risk statistics can be misleading without proper context, and how to weigh not only side effects, but also cost, inconvenience, and opportunity cost when deciding whether something is worth taking. Additionally, he discusses practical ways to evaluate whether a supplement is actually having a meaningful effect, how to think about discontinuing therapies, why supplements deserve far more skepticism than they often receive, and the small group of over-the-counter supplements he believes may offer a reasonable risk-reward trade-off. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #85 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits 

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this episode, Peter explores the complex and often misunderstood world of genetic testing, building a practical framework for understanding what these tests can and cannot actually tell us about health and disease. He explains why some genetic findings can be genuinely life-changing while many others offer information that is far more probabilistic than deterministic, and why directly measuring the phenotype is often more valuable than inferring risk from DNA alone. Peter examines where genetics can provide meaningful insight across the major disease categories and where its predictive power is far more limited than many people assume. He also discusses how to think critically about different types of genetic tests, how to interpret results in the proper context, and how to avoid the common trap of accumulating more genetic information without gaining greater clarity or actionable insight. We discuss: Genetic testing: understanding what it can reveal, where it falls short, and how to think about its clinical value [1:45]; The Human Genome Project: why decoding DNA did not immediately unlock the mysteries of disease [4:15]; The limitations of genetic testing: probabilistic risk, interpretive uncertainty, and the importance of phenotype [9:30]; Questions to ask when considering genetic testing [15:45]; Genetic testing in cardiovascular and metabolic disease: when genotype adds value beyond phenotype [17:00]; Genetic testing for inherited cardiac conditions: identifying hidden risk beyond routine screening [21:45]; Genetic testing for cancer risk: inherited syndromes, clinical utility, and the limits of consumer testing [24:00]; Genetic testing for ne

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this episode, Peter takes a deep dive into colorectal cancer (CRC) screening, explaining why it is one of the most preventable cancers and why getting screening right can have life-saving implications. He walks through how colorectal cancer develops and why it is uniquely well-suited to early detection and prevention, with a particular emphasis on the dual role of colonoscopy as both a diagnostic and therapeutic tool. Peter also examines the concerning rise in early-onset CRC among younger adults, highlighting why awareness and timely screening matter more than ever. The episode provides a practical guide to preparing for and evaluating the quality of a colonoscopy, including how to think about appropriate screening intervals and the real risks and tradeoffs involved. Finally, Peter explores the expanding landscape of non-invasive screening options, offering clear insight into what these alternatives can and cannot do so listeners can make informed decisions about their care at any age. We discuss: CRC statistics and goals for this episode [1:00]; Colorectal cancer development: polyp progression, risk types, and the window for prevention [4:00]; Why colorectal cancer is uniquely screenable: direct visualization and the dual role of colonoscopy [6:30]; Colonoscopy effectiveness: prevention through polyp removal and interpreting the NordICC trial data [8:15]; Rising colorectal cancer in younger adults: trends, possible causes, and the case for earlier screening [12:15]; Colonoscopy preparation: why bowel prep matters and how newer options improve the experience [16:45];

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this "Ask Me Anything" (AMA) episode, Peter answers listener questions across a wide range of topics, focusing on how to think through real-world trade-offs and apply scientific evidence in practice. He explores how to build and interpret a meaningful family health history, how individual risk tolerance influences decisions around testing and treatment, and why heart disease remains poorly prevented despite available tools. He also examines whether it's possible to carry excess body fat while remaining metabolically healthy, outlines the minimum effective dose for strength training for those with limited time, and discusses the habits and interventions most likely to reduce dementia risk. Additional topics include what evidence would need to emerge for him to reconsider his current stance on NAD-boosting supplements, and when hydration and electrolyte strategies are truly beneficial versus unnecessary. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #84 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss: Topics overview [1:15]; Us

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this episode, Peter explores one of the most foundational topics underlying nearly everything discussed on the podcast: how to think scientifically. Framed as an introspective deep dive, he examines why scientific thinking is inherently difficult for humans, the cognitive biases and tendencies that make it challenging to separate belief from evidence, and why these challenges are even more consequential in today's environment saturated with misinformation. He also offers a framework for improving our ability to evaluate claims, question assumptions, and identify a personal panel of experts, providing listeners with practical tools to become more disciplined and effective thinkers. We discuss: Topics to be covered and goals for this episode [2:00]; Scientific thinking: hypotheses, uncertainty, and the process of ruling out explanations [3:45]; How scientific knowledge differs from mathematical proof: useful approximations, evolving evidence, and acting under uncertainty [8:00]; Why scientific thinking is difficult: evolution, social instincts, and the need for deliberate practice [13:30]; Systems and tools designed to correct human bias [18:15]; How to think scientifically pt. 1: Notice when you're feeling certain [20:30]; How to think scientifically pt. 2: Judge the process, not just the conclusion [23:00]; How to think scientifically pt. 3: Notice when identity is shaping your beliefs [28:15]; How to think scientifically pt. 4: Don't confuse criticism with understanding [33:45]; How to think scientifically pt. 5: Outsource your thinking carefully [36:15];

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this episode, Peter takes a deep dive into prostate cancer screening, explaining why advanced and metastatic diagnoses continue to rise despite the availability of screening tools, and what can be done to reverse this trend. He breaks down what PSA actually measures and why it is far more informative when tracked over time rather than interpreted as a single value, and he explores how tools like MRI, PSA density, PSA velocity, and improved biopsy techniques can both reduce unnecessary procedures and improve the detection of aggressive cancers. Peter also discusses the role of active surveillance in avoiding overtreatment for low-risk cases, examines the flawed evidence that has historically been used to argue against PSA screening, and highlights how medications like finasteride can suppress PSA levels and potentially mask warning signs if not properly accounted for. Ultimately, he makes a compelling case for the importance of regular PSA testing as a key strategy in the effort to eliminate prostate cancer mortality. We discuss: The failure of current prostate cancer screening guidelines, and the rise in advanced disease despite available tools [2:30]; PSA screening fundamentals: benefits, harms, and the guideline shift driven by overdiagnosis concerns [5:30]; The impact of reduced PSA screening: rising rates of late-stage prostate cancer and worsening population-level outcomes [12:00]; How modern screening practices use PSA trends, MRI, and new imaging advances to improve accuracy and reduce unnecessary procedures [15:00]; Advances in prostate biopsy: transperineal approach improves safety and cancer

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this "Ask Me Anything" (AMA) episode, Peter explores the topic of gray-market peptides, one of the most requested and most confusing topics he's covered on The Drive. Peptides sit at the intersection of biological plausibility, clinical promise, and aggressive commercialization, and are often marketed as cutting-edge therapies for everything from muscle repair and longevity to cosmetic enhancement. Rather than promoting or dismissing peptides wholesale, Peter lays out a clear, repeatable framework for evaluating any peptide or drug—covering mechanism, intended effects, safety, dosing, and alternatives. He distinguishes FDA-approved peptide therapeutics from the loosely regulated "peptides" common in biohacking culture; examines the strengths and limitations of animal and human evidence; unpacks manufacturing, gray-market sales, "research use only" labeling, and third-party testing; addresses oral peptides and absorption challenges; and explains how patents and incentives shape which compounds advance through clinical pipelines. The discussion concludes with a sober look at what would need to change for peptides to become broadly usable therapies, where legitimate peptide therapeutics may expand next, and which areas of medicine stand to benefit most right now. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #8

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this episode, Peter takes a deep dive into the science and application of aging clocks, unpacking what they are, the differences between chronological age, biological age, and the pace of aging, and what epigenetic clocks may actually be measuring. He explores key research in the field, including a randomized controlled trial that tested simple lifestyle interventions against several commonly used aging clocks, as well as a study using brain MRI to assess the pace of aging and its relationship to dementia risk and mortality. Throughout the episode, Peter highlights the promises and pitfalls of these tools, ultimately focusing on the field's central question: whether improving an aging clock score truly translates into meaningful clinical outcomes. We discuss: Why aging clocks are being used as proxies for long-term health outcomes and the uncertainty surrounding their clinical value [2:00]; How aging clocks use DNA methylation to predict age and how they compare to traditional mortality prediction models [5:00]; The shift from aging clocks that predict chronological age to newer models that aim to measure biological age, lifespan differences, and the pace of aging [11:45]; The limitations of second-generation aging clocks: biological and measurement noise affecting reliability and interpretation [14:45]; Why aging clocks are exciting tools—compression, speed, and individual feedback [17:15]; The DO-HEALTH randomized trial: the study design and how different aging clocks were used to measure biological age and the pace of aging [22:00]; The DO-HEALTH study results: findings, takeaways, and open questions [27:45]; The DunedinPACNI study: how the model was developed and w

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this "Ask Me Anything" (AMA) episode, Peter answers listener questions across a wide range of topics, focusing on practical decision-making and real-world application. He explores how health priorities and strategies should evolve across different decades of life, which chronic diseases are most challenging to manage and how to think about risk hierarchies, and which emerging interventions—beyond exercise—show the most promise for dementia prevention. Peter also breaks down the utility of wearables and explains how to use and interpret DEXA scans effectively. He discusses the challenges of behavior change and how to make healthy habits stick, along with training strategies for balance, stability, and injury resilience, drawing lessons from his own setbacks. Additional topics include high-protein diets and mTOR, how to weigh mechanisms versus outcomes, how to evaluate diet sodas and non-nutritive sweeteners in context, and a range of listener questions covering health fads, emotional health, and sleep routines. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #82 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits 

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this special episode, Peter takes a deep dive into obicetrapib, an investigational drug that has captured his attention and renewed interest in an entire class of therapies known as CETP inhibitors. He explains what obicetrapib is and how it works, revisits the history of CETP inhibitors and why earlier versions of these drugs failed—sometimes dramatically—and breaks down the key clinical trials designed to evaluate their impact on cardiovascular risk. Peter examines how obicetrapib influences major lipid biomarkers, including LDL cholesterol and lipoprotein(a) [Lp(a)], and discusses emerging evidence from a study that explored the drug's effects on Alzheimer's-related blood biomarkers. He also highlights intriguing findings in individuals carrying the APOE4 allele and reflects on what these early results may mean for both cardiovascular disease prevention and potential implications for Alzheimer's risk, as well as how he is thinking about this therapy in the context of caring for his own patients. We discuss: Introducing obicetrapib: CETP inhibitor history, lipid biology, and early Alzheimer's biomarker signals in APOE4 carriers [2:15]; CETP biology explained: lipoproteins, reverse cholesterol transport, and how CETP inhibition alters HDL and LDL particles [5:15]; The early CETP inhibitor story: why raising HDL cholesterol alone failed to deliver cardiovascular protection [13:45]; The rise and fall of early CETP inhibitors: torcetrapib, dalcetrapib, evacetrapib, and anacetrapib [18:30]; Why obicetrapib may succeed where earlier CETP inhibitors failed [23:30]; The BROADWAY trial: obicetrapib's effects on LDL, ApoB, Lp(a), and residual cardiovascular risk [26:00]; Brain lipid

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Layne Norton is a nutrition scientist and accomplished power athlete,who returns to The Drive for a conversation that departs from the show's usual format. In this episode, Layne presents the evidence-based case that seed oils are not uniquely harmful under isocaloric conditions, while Peter steelmans the strongest versions of the opposing argument that seed oils are inherently harmful. They examine how scientific bias and evidence are evaluated, revisit the historical randomized controlled trials that shaped the seed oil controversy, and explore the mechanistic biology underlying LDL oxidation and atherosclerosis. Along the way, Layne unpacks the chemistry and processing of modern seed oils, assesses evolutionary and ancestral nutrition arguments, clarifies the relationship between seed oils, ultra-processed foods, and contemporary dietary patterns, and situates these questions within the larger context of lifestyle factors that drive cardiometabolic health. Layne concludes by offering practical considerations around dietary fats, cooking oils, and real-world food choices. We discuss: The idea behind this episode, biases, and evidence-based thinking [5:15]; The four core arguments behind claims that seed oils are harmful [12:30]; The Minnesota Coronary Experiment (MCE) [14:30]; The differences among saturated, monounsaturated, polyunsaturated, and trans fats, and why those differences matter for cardiovascular disease [18:30]; Missing trans fat data as a confounder in the Minnesota Coronary Experiment, other limitations of that study, and the challenge detecting meaningful differences in hard outcomes through nutrition research [24:00]; The Sydney Diet Heart Study (SDHS): an attem

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this "Ask Me Anything" (AMA) episode, Peter brings together his most up-to-date thinking on cardiorespiratory fitness into a single, practical guide designed to help listeners structure training for maximal impact on healthspan, lifespan, and long-term independence. He explains why cardiorespiratory fitness is one of the strongest modifiable predictors of longevity, clarifies what zone 2 training actually represents and how it differs from higher-intensity work, and addresses persistent confusion around exercise volume, intensity, and time constraints. The discussion covers how to measure and track progress in zone 2, VO₂ max targets and age-adjusted goals, planning for the marginal decade, and how to balance zone 2 with higher-intensity training across different weekly volumes. Peter also outlines how cardio training should be tailored for beginners, experienced trainees, and older adults, with special considerations for women and guidance on avoiding the most common cardio-training mistakes. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #79 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here.